As of November 14, 2026, Lifecore Biomedical, Inc. \De\ has reported one leadership change filing to the SEC under Item 5.02 of Form 8-K, on June 5, 2026 (Form 8-K, June 5, 2026).
29 companies changed executives this week, 1 had other signals.
Companies that just changed executives, and the new executive. Before you unlock: the company, the change and what is inside. After: the executive named with their role, how to reach the company, and a person's email only when we found one.
| ONITY GROUP INC. | announced the departure of its Chief Investment Officer | |
| Adicet Bio, Inc. | announced the departure of its Director | |
| MAMMOTH ENERGY SERVICES, INC. | announced the departure of its Chief Operating Officer | |
| CERENOME, INC. | named a new Director | |
| Cohen & Co Inc. | named a new Chief Executive Officer |
Sell to companies like Lifecore Biomedical, Inc. \De\? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Lifecore Biomedical, Inc. \De\ reported a change among its directors and officers to the SEC on Form 8-K, Item 5.02, on 2026-06-05. Every row below is cited to the filing it comes from, and this page adds each new change as Lifecore Biomedical, Inc. \De\ files it.
Layoffs on record: about 46 jobs, latest 2024-07-12 (layoff filings and notices).
Also on the record for Lifecore Biomedical, Inc. \De\
| Date | Record | Figure | Our page | Source |
|---|---|---|---|---|
| September 29, 2026 | Stake report, Schedule 13D/A, by Wynnefield Partners Small Cap Value, L.P. I | 14.3% of the class | 5%+ stakes | Source |
| September 28, 2026 | Stake report, Schedule 13D/A, by Legion Partners Asset Management, LLC | 17.3% of the class | 5%+ stakes | Source |
| July 29, 2026 | Stake report, Schedule 13G, by BlackRock, Inc. | 5.4% of the class | 5%+ stakes | Source |
| July 2, 2026 | Stake report, Schedule 13D/A, by 22NW Fund, LP | 6.74% of the class | 5%+ stakes | Source |
| July 2, 2026 | Stake report, Schedule 13D/A, by Legion Partners Asset Management, LLC | 17.1% of the class | 5%+ stakes | Source |
| April 27, 2026 | Stake report, Schedule 13G/A, by BlackRock, Inc. | 4.98% of the class | 5%+ stakes | Source |
| January 21, 2026 | Stake report, Schedule 13G, by BlackRock, Inc. | 5.1% of the class | 5%+ stakes | Source |
| October 17, 2025 | Stake report, Schedule 13G/A, by BlackRock, Inc. | 4.9% of the class | 5%+ stakes | Source |
| July 17, 2025 | Stake report, Schedule 13G, by BlackRock, Inc. | 5% of the class | 5%+ stakes | Source |
Selling to them or working with them? See who runs Lifecore Biomedical, Inc. \De\ now and the warning signs.
Free to see. No signup.
Keep reading
More on Lifecore Biomedical, Inc. \De\ and the records around it.
Lifecore Biomedical, Inc. \De\ elsewhere on the record
- 5%+ stake filings Sep 2026
- Who owns it
Companies that share a holder
- Legion Partners, L.P. I also filed stake reports on 2 other companies: NN INC (Aug 2026), Clear Channel Outdoor Holdings, Inc. (Jun 2026)
- 22NW Fund, LP also filed stake reports on 7 other companies: PhenixFIN Corp (May 2026), FARMER BROTHERS CO (May 2026), FOSTER L B CO (Apr 2026)
- BlackRock, Inc. also filed stake reports on 1596 other companies: AvePoint, Inc. (Nov 2026), BIOMARIN PHARMACEUTICAL INC (Nov 2026), MSG RANGERS CORP (Nov 2026)
Watch Lifecore Biomedical, Inc. \De\
Get an email when Lifecore Biomedical, Inc. \De\ files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on Lifecore Biomedical, Inc. \De\?
Example from a real report (our sample on Target): “Target eliminated approximately 1,800 corporate positions, with around 1,000 employees receiving layoff notices and the remainder accounted for by eliminating open roles.” Source: NBC News
A Full Report on Lifecore Biomedical, Inc. \De\: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Lifecore Biomedical, Inc. \De\ covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
11 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
Timeline
| Filed | In / out | Person | Role | Effective | Source |
|---|---|---|---|---|---|
| 2026-06-05 | Reported | not named in the filing | 8-K, 2026-06-05 |
New leaders reset buying decisions — get the Full Report on Lifecore Biomedical, Inc. \De\: who runs it, how the money works and what to watch, every claim linked to its source.
Get the Full ReportFind people with the same kind of experience as the senior executive at Lifecore Biomedical, Inc. \De\, with the record behind each one.
Find candidates like senior executive at Lifecore Biomedical, Inc. \De\Every change, in the filing's words
Reported
By its terms, the 2026 Plan will become effective on October 16, 2026 (the "Effective Date") at which time the Company's 2019 Stock Incentive Plan (the "2019 Plan") will expire by its terms.
- On June 4, 2026, Lifecore Biomedical, Inc. (the "Company") held its 2026 annual meeting of stockholders (the "Annual Meeting").
- At the Annual Meeting, Company's stockholders approved Proposal No. 4: Approval of the Lifecore Biomedical, Inc. 2026 Stock Incentive Plan (the "2026 Plan").
- The Board of Directors adopted the 2026 Plan on April 22, 2026, on the Compensation Committee's recommendation, subject to stockholder approval.
- The aggregate number of shares of the Company's Common Stock available for issuance under the 2026 Plan will be (i) 2,500,000 shares of Common Stock, plus (ii) any shares of Common Stock that are represented by awards granted under the 2019 Plan that are forfeited, expire or are cancelled without delivery of shares or which result in the forfeiture of shares back to the Company on or after the Effective Date.
Tools for this story
Each opens in a new tab, filled in for Lifecore Biomedical, Inc. \De\. With no account yet, you sign up free and land on the result.
Where this comes from
A public company must file a current report on Form 8-K with the SEC within four business days when a director leaves or is elected, or when its chief executive, chief financial, chief accounting or chief operating officer, or another named executive, departs or is appointed. That disclosure goes under Item 5.02 of the report.
Every change on this page is taken from one of those filings and quoted in the company's own words, with a link to the filing, so it can be checked at the source. Where a filing names the person, the role and the date a change takes effect, they are shown beside the quote. Where it does not, the quote stands on its own. A filing states what changed; it rarely states why, and neither does this page.
